An Unbiased View of BMS-199264 hydrochloride
All enrolled clients who received at least a single dose of zosuquidar or placebo during induction have been monitored with the occurrence of adverse functions (439 clients, 219 on zosuquidar and 210 on placebo). The commonest adverse events had been relevant to the duration of prolonged and major myelosuppression as is expected with induction chem